Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 6Breast Neoplasms 6Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Sarcoma 3Osteosarcoma 3Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neurofibrosarcoma 2Liposarcoma 2Leukemia, T-Cell 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Fallopian Tube Neoplasms 2Chondrosarcoma, Extraskeletal Myxoid 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1The Neoadjuvant Therapy 1Sezary Syndrome 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Renal Pelvis and Ureter Urothelial Carcinoma 1Perivascular Epithelioid Cell Neoplasms 1Nerve Sheath Neoplasms 1Neoplasms, Connective and Soft Tissue 1

Interventions

Triptorelin Pamoate 1Paclitaxel 1Fulvestrant 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × The Neoadjuvant Therapy × Doxorubicin × Clear all
NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡